- Home
- ALIS vs VRCA Comparison
ALIS vs VRCA Comparison
Compare ALIS & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALIS | VRCA |
|---|---|---|
| Founded | 2024 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.9M | 88.0M |
| IPO Year | 2024 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ALIS | VRCA |
|---|---|---|
| Price | $8.51 | $3.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $13.83 |
| AVG Volume (30 Days) | 25.3K | ★ 51.9K |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $58.01 |
| P/E Ratio | $204.75 | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $7.70 | $3.28 |
| 52 Week High | $14.91 | $9.82 |
Technical Indicators
Market Signals| Indicator | ALIS | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 44.02 | 37.19 |
| Support Level | $7.70 | N/A |
| Resistance Level | $10.17 | $5.94 |
| Average True Range (ATR) | 1.41 | 0.35 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 17.39 | 24.32 |
Price Performance
Historical ComparisonAbout ALIS Calisa Acquisition Corp Ordinary shares
Calisa Acquisition Corp is a blank check company with the purpose of effecting a merger, asset acquisition, stock exchange, stock purchase, reorganization, or similar business combination.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.